Zobrazeno 1 - 10
of 29
pro vyhledávání: '"T V, Kropotina"'
Autor:
E. L. Nasonov, V. I. Mazurov, A. M. Lila, T. V. Dubinina, I. Z. Gaydukova, S. A. Lapshina, A. A. Klimenko, D. V. Somov, S. A. Lukianov, D. M. Chudakov, I. V. Zvyagin, O. V. Britanova, M. A. Korolev, D. I. Abdulganieva, D. G. Krechikova, A. A. Kastanayan, L. V. Eliseeva, R. R. Samigullina, T. V. Povarova, O. V. Antipova, S. A. Smakotina, V. N. Soboleva, O. B. Nesmeyanova, T. V. Plaksina, N. F. Soroka, I. B. Vinogradova, A. P. Rebrov, T. V. Kropotina, A. L. Maslyanskiy, A. V. Zinkina-Orikhan, Yu. N. Lin’kova, P. S. Pukhtinskaia, M. A. Morozova, G. A. Vinderskaya
Publikováno v:
Научно-практическая ревматология, Vol 62, Iss 1, Pp 65-80 (2024)
The aim – to evaluate the clinical effectiveness, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of seniprutug (BCD-180) in patients with radiographic active axial spondyloarthritis (r-axSpA, or ankylosing spondylitis).Subjects and
Externí odkaz:
https://doaj.org/article/38cd433e63d04c6c9e4e85e988370a30
Autor:
V. I. Mazurov, Sh. F. Erdes, I. Z. Gaydukova, T. V. Dubinina, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, E. S. Zhugrova, T. V. Plaksina, P. A. Shesternya, T. V. Kropotina, O. V. Antipova, E. A. Smolyarchuk, O. A. Tsyupa, D. I. Abdulganieva, S. A. Lapshina, D. G. Krechikova, I. G. Gordeev, O. B. Nesmeyanova, E. P. Ilivanova, A. V. Strelkova, V. V. Tyrenko, E. A. Mikhailova, A. V. Eremeeva
Publikováno v:
Современная ревматология, Vol 18, Iss 1, Pp 35-46 (2024)
The article presents the results of the three-year use of netakimab (NTK) in patients with ankylosing spondylitis (AS) as part of the phase III BCD-085-5/ASTERA study.Objective: to evaluate the long-term efficacy and safety of NTK over a three-year p
Externí odkaz:
https://doaj.org/article/35b1cb81150247aab4f58712cc2503b9
Autor:
T. V. Dubinina, A. B. Demina, E. M. Agafonova, Sh. F. Erdes, V. I. Mazurov, I. Z. Gaydukova, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, E. S. Zhugrova, T. V. Plaksina, P. A. Shesternya, T. V. Kropotina, O. V. Antipova, E. A. Smolyarchuk, O. A. Tsyupa, D. I. Abdulganieva, S. A. Lapshina, D. G. Krechikova, I. G. Gordeev, O. B. Nesmeyanova, V. V. Tyrenko, E. P. Ilivanova, A. V. Strelkova
Publikováno v:
Современная ревматология, Vol 17, Iss 6, Pp 52-58 (2023)
The article contains the data obtained during the 156-week follow-up of patients with ankylosing spondylitis (AS) in the ASTERA phase III study.Objective: to evaluate the effect impact of netakimab (NTK) on quality of life (QoL), back pain and work c
Externí odkaz:
https://doaj.org/article/21939fb7c39048f99cdce239380dea45
Autor:
T. V. Korotaeva, E. E. Gubar, E. Yu. Loginova, Y. L. Korsakova, E. A. Vasilenko, I.-D. Yu. Ilyevsky, L. V. Ivanova, E. Yu. Akulinushkina, P. A. Shesternya, O. V. Matveychuk, Yu. Yu. Grabovetskaya, A. A. Barakat, M. A. Korolev, E. V. Zonova, O. A. Georginova, I. V. Kolotilina, I. M. Marusenko, I. B. Vinogradova, O. B. Nesmeyanova, N. E. Grigoriadi, A. V. Petrov, D. G. Krechikova, T. V. Kropotina, S. P. Yakupova, V. I. Mazurov
Publikováno v:
Современная ревматология, Vol 17, Iss 6, Pp 22-30 (2023)
Psoriatic arthritis (PsA) is a chronic immunoinflammatory disease of the joints, spine and entheses from the group of spondyloarthritis, which is usually observed in patients with psoriasis. In recent years, the axial form of PsA (axPsA) has been act
Externí odkaz:
https://doaj.org/article/2ce507c9aff047a4aa939b461df954ab
Autor:
V. I. Mazurov, A. M. Lila, M. A. Korolev, A. M. Prystrom, A. V. Kundzer, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, T. V. Plaksina, O. V. Antipova, D. G. Krechikova, S. A. Smakotina, O. A. Tciupa, E. V. Puntus, T. A. Raskina, L. N. Shilova, T. V. Kropotina, O. B. Nesmeyanova, T. A. Popova, I. B. Vinogradova, E. A. Dokukina, A. V. Plotnikova, P. S. Pukhtinskaia, A. V. Zinkina-Orikhan, Yu. N. Linkova, A. V. Eremeeva, A. A. Lutckii, E. L. Nasonov
Publikováno v:
Научно-практическая ревматология, Vol 61, Iss 1, Pp 87-99 (2023)
Background. Previously, 24-week results of phase III double-blind, placebo-controlled randomized clinical study (SOLAR) of levilimab in subjects with active rheumatoid arthritis (RA) proved a superiority of levilimab over placebo. Here we present 1-y
Externí odkaz:
https://doaj.org/article/4769ca6bff3645e4857fcaa192e698f0
Autor:
V. I. Mazurov, M. A. Korolev, A. M. Prystrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, T. V. Plaksina, O. V. Antipova, D. G. Kretchikova, S. A. Smakotina, O. A. Tciupa, E. V. Puntus, T. A. Raskina, L. N. Shilova, T. V. Kropotina, O. B. Nesmeyanova, T. A. Popova, I. B. Vinogradova, Yu. N. Linkova, E. A. Dokukina, A. V. Plotnikova, P. S. Pukhtinskaia, A. V. Zinkina-Orikhan, A. V. Eremeeva, A. A. Lutckii
Publikováno v:
Современная ревматология, Vol 15, Iss 4, Pp 13-23 (2021)
Levilimab is anti-interleukin-6 receptor (IL6R) monoclonal antibody. The article presents data obtained during 24 weeks of the SOLAR phase III study.Objective: to confirm efficacy and safety of levilimab in combination with methotrexate (MTX) in pati
Externí odkaz:
https://doaj.org/article/e5807cdebb9f4373ba05f16f3438579e
Autor:
V. I. Mazurov, E. G. Zotkin, I. Z. Gaydukova, E. P. Ilivanova, T. V. Kropotina, T. V. Plaksina, O. B. Nesmeyanova, N. F. Soroka, E. A. Kunder, E. A. Dokukina, Yu. N. Linkova, N. A. Kravtsova, P. S. Pukhtinskaya, A. V. Eremeeva, A. V. Zinkina-Orikhan, A. A. Lutckii
Publikováno v:
Научно-практическая ревматология, Vol 59, Iss 2, Pp 141-151 (2021)
Levilimab (LVL) is a monoclonal antibody against the interleukin-6 receptor (IL6R). The article presents data obtained during 56 weeks of the AURORA phase II study.Objective: to evaluate the efficacy safety and immunogenicity of LVL in methotrexate (
Externí odkaz:
https://doaj.org/article/b875e4d7b7464abf86d0680266117122
Autor:
V. I. Mazurov, Sh. F. Erdes, I. Z. Gaydukova, T. V. Dubinina, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, E. S. Zhugrova, T. V. Plaksina, P. A. Shesternya, T. V. Kropotina, O. V. Antipova, E. A. Smolyarchuk, O. A. Tsyupa, D. I. Abdulganieva, S. A. Lapshina, D. G. Krechikova, I. G. Gordeev, O. B. Nesmeyanova, E. P. Ilivanova, A. V. Strelkova, A. V. Eremeeva, A. V. Zinkina-Orikhan
Publikováno v:
Современная ревматология, Vol 14, Iss 4, Pp 39-49 (2020)
Netakimab (NTK) is a humanized anti-interleukin-17A monoclonal antibody. To date, the drug has been approved to treat ankylosing spondylitis (AS), psoriatic arthritis, and plaque psoriasis. The paper gives the data obtained during 52-week follow-up o
Externí odkaz:
https://doaj.org/article/984673a23dad4308b93cdaa2748700af
Autor:
L. I. Alekseeva, S. A. Terpigorev, E. V. Zonova, L. M. Kudelya, N. M. Babadaeva, A. V. Teteneva, A. A. Kondrashov, D. N. Orlov, T. V. Raskina, O. N. Anoshenkova, Yu. P. Chasovskikh, T. V. Kropotina, A. B. Opongosheva, N. V. Yudina, N. G. Ganyukova
Publikováno v:
Бюллетень сибирской медицины, Vol 19, Iss 3, Pp 113-119 (2020)
The aim of the study was to develop ways to improve the diagnosis and treatment of systemic sclerosis (SSc)-ILD. Interstitial lung disease (ILD) is a common manifestation of SSc. In the territory of the Siberian Federal District (SFD), the number of
Externí odkaz:
https://doaj.org/article/ed3f55c0201841c4a4916cb184a1c1c4
Autor:
V. I. Mazurov, I. Z. Gaydukova, Sh. Erdes, T. V. Dubinina, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, E. S. Zhugrova, T. V. Plaksina, P. A. Shesternya, T. V. Kropotina, O. V. Antipova, E. A. Smolyarchuk, O. A. Tciupa, D. I. Abdulganieva, S. A. Lapshina, D. G. Krechikova, I. G. Gordeev, O. B. Nesmeyanova, V. V. Tyrenko, E. P. Ilivanova, A. V. Strelkova, A. V. Eremeeva
Publikováno v:
Научно-практическая ревматология, Vol 58, Iss 4, Pp 376-386 (2020)
Netakimab (NTK) is a humanized monoclonal antibody targeting interleukin-17A.Objective. The main objective of BCD-085-5/ASTERA study was to prove superiority of NTK over placebo and assess its’ safety in patients with active AS.Subjects and methods
Externí odkaz:
https://doaj.org/article/7a1a0bd45df54172a1cd35efba011387